Results 191 to 200 of about 70,073 (274)

PFKFB3 as a multifaceted driver and therapeutic target in castration-resistant prostate cancer. [PDF]

Cell Death Dis
Chen L, Xu YX, Ren YY, Wang ZD, Dong XM, Chen YM, Wu P, Wu T, Xiang F, Xie T, Zhang Q, Zhou JL.   +11 more
europepmc   +1 more source

Current status of radionuclide therapies in metastatic castration-resistant prostate cancer. [PDF]

Ther Adv Med Oncol
Fei X, Huang RD, Zhou X, Ye SJ, Nan N, Wang KJ, Ma Q.   +6 more
europepmc   +1 more source

Correction: Phosphorylation-dependent regulation of SPOP by LIMK2 promotes castration-resistant prostate cancer. [PDF]

Br J Cancer
Nikhil K, Haymour HS, Kamra M, Shah K.
europepmc   +1 more source

Integrative bulk and single-cell transcriptomics link EZH2 to immunosuppressive programs and tumor-Treg crosstalk in castration-resistant prostate cancer. [PDF]

Front Immunol
Xiong X, Xie J, Dai P, Cheng C, Liu J, Huang G.   +5 more
europepmc   +1 more source

Emerging Therapeutic Approaches to Engage the Androgen Receptor for the Treatment of Castration-Resistant Prostate Cancer. [PDF]

Cancers (Basel)
Henry I, Foreman R, Balachandran L, Mortimer E, Asim M.   +4 more
europepmc   +1 more source

Identification of Actionable Mutations in Metastatic Castration-Resistant Prostate Cancer Through Circulating Tumor DNA: Are We There Yet? [PDF]

Curr Oncol
Tao W, Sabel A, Bonfil RD.
europepmc   +1 more source

Characterization and validation of a bone metastatic castration-resistant prostate cancer model as a nanomedicine evaluation platform. [PDF]

Theranostics
Serrano-Martí A, Armiñán A, Conejos-Sánchez I, Mittermüller D, Li SW, Lackschewitz PT, Roselló-Sastre E, Gunzer M, Cabral H, Vicent MJ.   +9 more
europepmc   +1 more source

Population Pharmacokinetics Analysis of Talazoparib and Enzalutamide Combination Therapy for Patients With Metastatic Castration-Resistant Prostate Cancer. [PDF]

J Clin Pharmacol
Hadigol M, Williams JH, Shi H, Yang DZ, Hoffman J, Wang DD.   +5 more
europepmc   +1 more source

Exploratory case series of circulating tumor DNA dynamics during tandem therapy in metastatic castration-resistant prostate cancer. [PDF]

EJNMMI Res
Amghar M, Rausch T, Özgür H, Roscher M, Bauder-Wüst U, Bruchertseifer F, Morgenstern A, Beneš V, Kratochwil C, Benešová-Schäfer M.   +9 more
europepmc   +1 more source